A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)

  • End date
    Aug 11, 2023
  • participants needed
  • sponsor
    Hutchison Medipharma Limited
Updated on 11 February 2021


Fruquintinib once daily in 4 weeks treatment cycle (three weeks on and one week off) in combination with Paclitaxel 80mg/day1, 8, 15 of 4 weeks cycle) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with advanced GC in ph1b/2 study. This study is aimed to evaluate the efficacy and safety of Fruquintinib in combination with Paclitaxel in the treatment of patients with aGC who have progressed after first line standard chemotherapy.


This is a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial to compare the efficacy and safety of Fruquintinib combined with Paclitaxel versus Paclitaxel alone in patients with advanced gastric cancer who have progressed after first-line standard chemotherapy. After checking eligibility criteria, subjects will be randomized into Fruquintinib combined with Paclitaxel group (treatment group) or placebo combined with Paclitaxel group (control group) in a ration of 1:1. Primary Efficacy Endpoint: Overall Survival (OS). Secondary Efficacy Endpoints: Progression free survival (PFS) (According to RECIST Version 1.1), Objective Response Rate (ORR), Disease Control Rate (DCR), . Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 4.03.

Condition Advanced Gastric Cancer
Treatment fruquintinib +paclitaxel, fruquintinib placebo + paclitaxel
Clinical Study IdentifierNCT03223376
SponsorHutchison Medipharma Limited
Last Modified on11 February 2021


Yes No Not Sure

Inclusion Criteria

Signed informed consent
Histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma
Metastatic disease or locally advanced, unresectable disease
Disease progression during or within 4 months after the last dose of the first-line therapy (with platinum/fluoropyrimidine )
Adequate hepatic, renal, heart, and hematologic functions
At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)
Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure
Good performance status Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 1

Exclusion Criteria

Pregnant or lactating women
Any factors that influence the usage of oral administration
Evidence of CNS metastasis
Intercurrence with one of the following: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure
Abuse of alcohol or drugs
Less than 4 weeks from the last clinical trial
Previous treatment with VEGFR inhibition
Disability of serious uncontrolled intercurrence infection
Proteinuria 2+ (1.0g/24hr)
Have evidence or a history of bleeding tendency within two months of the enrollment randomization, regardless of seriousness
Within 12 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc
Within 6 months before the first treatment occurs acute myocardial infarction, acute coronary syndrome or CABG
Bone fracture or wounds that was not cured for a long time
Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant Therapy
The tumor invades a large vessel structure, such as the pulmonary artery, superior vena cava, or inferior vena cava
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note